Drugs / Recombinant hep B vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00831311 Comparator | Oct 2004 → Nov 2005 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant hep B vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00831311 ↗ |
| Modality | Vaccine | “Pentaxim and Engerix B Pediatrico (Hep B monovalent) vaccines” PMID 21372751 ↗ Jun 2011 |
| Route | Intramuscular | “0.5 mL, Intramuscular (right and left thighs, respectively)” NCT00831311 ↗ |